Please login to the form below
linaclotide
This page shows the latest linaclotide news and features for those working in and with pharma, biotech and healthcare.
China approves Ironwood Pharma’s IBS treatment
AstraZeneca '. primarily responsible' on commercialisation across the vast country. Tom McCourt, Ironwood's new president said: “Regulatory approval in China represents another important step in bringing linaclotide to millions of adult
Latest news
-
Shire bags US approval for constipation drug Motegrity
Linzess (linaclotide) – which brought in almost $575m in sales for Allergan in the first nine months of the year – works by binding to intestinal epithelial cells and stimulating the secretion of
-
NICE backs Allergan's IBS therapy Truberzi
includes Linzess (linaclotide) for IBS with constipation.
-
FDA approves Synergy's constipation drug Trulance
Plecanatide's closest competitor in the market is Ironwood/Allergan's Linzess/Constella (linaclotide), described as a guanylate cyclase stimulant, which is approved for the treatment of constipation-predominant IBS in
-
AZ and Ironwood to file IBS drug linaclotide in China next year
Phase III trial of linaclotide show it improved symptoms such as abdominal pain. ... AstraZeneca (AZ) and Ironwood Pharmaceuticals say they are on course to submit irritable bowel syndrome treatment linaclotide for approval in China in early 2016.
-
Forest Labs agrees $1.46bn deal to buy Furiex
sit well in its portfolio alongside constipation-predominant IBS drug Linzess (linaclotide).
More from news
Approximately 2 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Oral biologics delivery still elusive
years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome.
-
Pharma deals during October 2012
In addition, Ironwood could receive a further $125m in milestones if certain sales targets for linaclotide are met. ... 153. Ironwood / AstraZeneca. Co-develop &co-commercialise (profit/ loss share). Linaclotide, IBS with constipation (FDA approved).
-
Interview: Jorge Gallardo, Almirall
pulmonary disease (COPD) and linaclotide indicated for irritable bowel syndrome with constipation, for which there is no specific treatment approved by the European Medicines Agency (EMA).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Ironwood appoints Edward Owens to board
Owens is a former partner at investments advisor Wellington Management, and joins the US-based biopharma at a time of growth following the approval of Linzess (linaclotide) in the US for
-
Ironwood promotes Dr Mark Currie
Currie's academic research on the guanylate cyclase-C (GC-C) pathway laid the foundation for the discovery by Ironwood scientists of linaclotide. ... Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe,
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
